BRD2 and non-small cell lung carcinoma: CCR6+ Tregs are enriched in human solid tumors such as NSCLC, HNSCC, laryngeal and esophageal SCC and chemotherapy-resistant CRC compared to NAT and PBMC (see, also Figure 2) and are associated with tumor progression [117,118,119,120,121].